Corinne Jenkins
Stock Analyst at Goldman Sachs
(3.53)
# 1,033
Out of 4,413 analysts
59
Total ratings
51.22%
Success rate
5.11%
Average return
Main Sectors:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITCI Intra-Cellular Therapies | Maintains: Neutral | $67 → $77 | $72.73 | +5.87% | 4 | Apr 17, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $16 → $18 | $11.21 | +60.57% | 5 | Apr 3, 2024 | |
| GERN Geron | Maintains: Buy | $4 → $5 | $4.08 | +22.55% | 3 | Mar 15, 2024 | |
| TGTX TG Therapeutics | Maintains: Neutral | $12 → $13 | $15.88 | -18.14% | 6 | Feb 29, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $42 → $52 | $41.43 | +25.51% | 7 | Jan 26, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $36 → $53 | $41.18 | +28.70% | 4 | Jan 26, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $7.07 | +83.88% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $30.27 | -7.50% | 7 | Jan 9, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Buy | $47 → $52 | $46.84 | +11.02% | 5 | Nov 29, 2023 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $12 → $4 | $2.54 | +57.48% | 5 | Aug 15, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $27 → $23 | $8.18 | +181.17% | 2 | Mar 15, 2023 | |
| ACRS Aclaris Therapeutics | Maintains: Buy | $25 → $21 | $1.26 | +1,566.67% | 2 | Mar 7, 2023 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $9 → $14 | $5.08 | +175.59% | 2 | Dec 20, 2022 | |
| GRTS Gritstone bio | Downgrades: Sell | $2 | $0.87 | +128.91% | 1 | Aug 22, 2022 | |
| RDUS Radius Health | Maintains: Neutral | $9 → $8 | $17.31 | -53.78% | 2 | May 24, 2022 | |
| ATHA Athira Pharma | Initiates: Neutral | n/a | $2.04 | - | 1 | Dec 15, 2021 |
Intra-Cellular Therapies
Apr 17, 2024
Maintains: Neutral
Price Target: $67 → $77
Current: $72.73
Upside: +5.87%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $16 → $18
Current: $11.21
Upside: +60.57%
Geron
Mar 15, 2024
Maintains: Buy
Price Target: $4 → $5
Current: $4.08
Upside: +22.55%
TG Therapeutics
Feb 29, 2024
Maintains: Neutral
Price Target: $12 → $13
Current: $15.88
Upside: -18.14%
Rhythm Pharmaceuticals
Jan 26, 2024
Maintains: Buy
Price Target: $42 → $52
Current: $41.43
Upside: +25.51%
IDEAYA Biosciences
Jan 26, 2024
Maintains: Buy
Price Target: $36 → $53
Current: $41.18
Upside: +28.70%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $7.07
Upside: +83.88%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $30.27
Upside: -7.50%
SpringWorks Therapeutics
Nov 29, 2023
Maintains: Buy
Price Target: $47 → $52
Current: $46.84
Upside: +11.02%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $12 → $4
Current: $2.54
Upside: +57.48%
RAPT Therapeutics
Mar 15, 2023
Maintains: Buy
Price Target: $27 → $23
Current: $8.18
Upside: +181.17%
Aclaris Therapeutics
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $1.26
Upside: +1,566.67%
Terns Pharmaceuticals
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $5.08
Upside: +175.59%
Gritstone bio
Aug 22, 2022
Downgrades: Sell
Price Target: $2
Current: $0.87
Upside: +128.91%
Radius Health
May 24, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $17.31
Upside: -53.78%
Athira Pharma
Dec 15, 2021
Initiates: Neutral
Price Target: n/a
Current: $2.04
Upside: -